Drug intelligence / Profile preview

technetium (99mTc) succimer (V)

Development stage
Unknown
Lead developer
GE Healthcare
Modality
Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Gamma Emitters → Radiopharmaceuticals, Small Molecules
Administration
Intravenous
01

Overview

Technetium (99mTc) succimer (V), also known as pentavalent Tc-99m DMSA, is a radiopharmaceutical used primarily for the diagnostic imaging of medullary thyroid carcinoma (MTC). Unlike the more common trivalent form (Tc-99m DMSA (III)), which is used for renal cortical imaging, the pentavalent form is prepared under alkaline conditions (typically by adding sodium bicarbonate to a standard DMSA kit) to achieve the +5 oxidation state of technetium. It functions as a tumor-seeking agent, with its mechanism of action believed to involve the mimicry of phosphate ions ($PO_4^{3-}$), leading to uptake in tissues with high metabolic activity or microcalcifications. It is particularly valued for detecting recurrences and metastases of MTC when calcitonin levels are elevated but conventional imaging is negative. Beyond MTC, it has been investigated for imaging soft tissue sarcomas, bone metastases, and systemic amyloidosis.

Other names
pentavalent technetium-99m dimercaptosuccinic acidtechnetium-99m dimercaptosuccinic acid (V)Tc-99m DMSA (V)pentavalent technetium-99m succimer
02

Targets

POU1F1 (POU class 1 homeobox 1)SLC superfamily (Solute carrier superfamily)

Beyond the preview

Go deeper on technetium (99mTc) succimer (V).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on technetium (99mTc) succimer (V).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call